This article provides a comprehensive comparison/analysis of the societal impact of different healthcare models in the US by 2026, evaluating outcomes for three major systems and offering critical insights into their future implications for public health and economic stability.

New federal laws are set to significantly alter the landscape of drug pricing in the U.S., with a clear objective to reduce costs by 15% for American consumers by 2026, promising substantial financial relief.